Keywords: Aegis Therapuetics, Dr Reddy's, Roche, Intravail, ProTek, Licensing
Aegis Therapeutics and Dr Reddy's in strategic alliance for Intravail
Article | 26 January 2010
Dr Reddy's Laboratories, India’s second-largest drugmaker, and San Diego, USA-based Aegis Therapeutics have entered into a partnership providing Dr Reddy's with access to Aegis' Intravail drug delivery technology for certain undisclosed therapeutics currently being marketed with annual worldwide sales in excess of $1 billion. Financial terms of the deal were not disclosed.
Commenting on the collaboration, Raghav Chari, senior vice president - Proprietary Products business, at the Indian firm, said, "We are extremely pleased to be working with Aegis and gaining access to their patented Intravail drug delivery technologies. Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Want to read the full article?
Take a 30 day FREE Trial worth £60
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Ono Pharma buys Japanese rights to two cancer drugs in $340 million deal with Onyx
- GlaxoSmithKline sells Croatian research center to Galapagos, names new CFO and enters supply deal with Lonza; EMEA update on Avandia and Pandemrix
- Wyeth/Pfizer accused of using ghostwritten articles to overstate benefits of HRT
- China’s liver cancer drug market forecast to nearly triple to $144 million in 2014
- International sales rep quality survey views BRIC markets
